Special Issue "Molecular Classification of Human Cancer: Diagnosis and Treatment 2016"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 December 2016).
Dr. William Chi-shing Cho
Queen Elizabeth Hospital, Hong Kong, China
Interests: cancer biomarker; chinese medicine; diabetes mellitus; evidence-based medicine; genomics; microRNA; molecular diagnostics; nasopharyngeal carcinoma; non-small cell lung cancer; proteomics
Worldwide, human cancer occurs with increasingly higher incidences and mortalities. The traditional diagnostic practice for this disease is mainly based on histological patterns. Recent research supports the notion that cancer is not a single malignant disorder, but rather, a group of distinct molecular diseases. In the era of precision medicine with targeted therapies, there is an imperative need to overcome the limitations of the conventional classification system, so as to accurately stratify patients to achieve maximum therapeutic efficacy. As such, many molecular diagnostic tests have been developed to identify the underlying genetic signatures and incorporate them into the conventional histopathological classifications of cancers.
The profiling of cancer has yielded a number of genetic, microRNA, proteomic, metabolic, and imaging markers for molecular classification. Newer approaches include, but are not limited to, cancer stem cell analysis and next-generation sequencing. Indeed, molecular classification has already been extensively applied to some types of cancer, such as the subtypes of luminal A and lumina B estrogen receptor-positive breast cancer, the subtypes of ALK- and EGFR-positive non-small cell lung cancer, the subtypes of WNT pathway and Sonic Hedgehog pathway medulloblastoma, etc. This Special Issue discusses the significance of molecular classification and its impact on the diagnosis of, and rational therapy for cancer.
Dr. William Chi-shing Cho
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer biomarker
- cancer stem cells
- clinical trial
- copy number variation
- diagnostic imaging
- digital PCR
- fluorescence in situ hybridization
- genome-wide association studies
- genomic database
- microfluidics, nanofluidics
- molecular classification
- molecular diagnostics
- molecular tumor pathology
- next-generation sequencing
- non-coding RNAs
- PCR array
- personalized medicine
- post-translational modifications
- precision medicine
- single nucleotide polymorphism
- targeted therapy
- translational cancer research